• 18 JUN 2021

    PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available

    LAGUNA HILLS, CA, June 18, 2021–(BUSINESS WIRE)—PharmaCyte Biotech, Inc. (“Company”) (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box® , announced today that its 2021 Annual Meeting of Stockholders, held on June 16, 2021, has been adjourned until June 30, 2021, at 11:00

    Read more →
    • 14 JUN 2021

    PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders

    LAGUNA HILLS, CA, June 14, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that this week’s Annual Meeting of Shareholders will be held virtually on Wednesday, June 16, 2021, at 11:00 A.M., Pacific

    Read more →
    • 01 APR 2021

    PharmaCyte Biotech Successfully Completes 1 Year Stability Study

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the twelve-months product stability testing required by the U.S. Food and Drug Administration (FDA) for its CypCaps™ final clinical trial

    Read more →
    • 26 JAN 2021

    PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product

    LAGUNA HILLS, CA, January 26, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has commenced additional studies to determine the exact sequence of the DNA encoding of the enzyme in the cells of its CypCaps® product for pancreatic

    Read more →
    • 14 DEC 2020

    PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product

    LAGUNA HILLS, CA, December 14, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has commenced additional physical parameter testing of its CypCaps® product for pancreatic cancer, in line with the recommendations

    Read more →
    • 02 DEC 2020

    PharmaCyte Biotech Successfully Completes 9-Month Stability Study

    LAGUNA HILLS, CA, December 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration

    Read more →
    • 04 NOV 2020

    PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) with respect to its Investigational New Drug Application (IND).

    Read more →
    • 02 OCT 2020

    PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U. S. FDA

    LAGUNA HILLS, CA, October 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the company’s submitted Investigational New Drug

    Read more →
    • 23 SEP 2020

    PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

    LAGUNA HILLS, CA, September 23, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it continues to engage with the U.S. Food and Drug Administration (FDA) during its 30-day comment period regarding

    Read more →
    • 14 SEP 2020

    PharmaCyte Biotech Successfully Completes Six-Month Stability Study

    LAGUNA HILLS, CA, September 14, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the six-month product stability testing that is required by the U.S. Food and Drug

    Read more →